Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas

Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Felicia A. Hanzu(Hospital Clínic de Barcelona), Isabel Tena(Fundación Hospital Provincial de Castellón), C. Ferrer Albiach(Fundación Hospital Provincial de Castellón), Enrique Mercader-Cidoncha(Hospital General Universitario Gregorio Marañón), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), F. Matute Teresa(Hospital Clínico San Carlos), Miguel Arístegui(Hospital General Universitario Gregorio Marañón), Mercedes Mitjavila(Hospital Universitario Puerta de Hierro Majadahonda), Cristina Álvarez-Escolá(Hospital Universitario La Paz), María Rosa Bella(Universitat Autònoma de Barcelona)
Clinical & Translational Oncology
May 6, 2021
10.1007/s12094-021-02622-9
Cited by 169

Related Papers

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
|The Lancet|2023|319